Ying Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Qiu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Bin Wei
School of Life Sciences, Shanghai University, Shanghai 200444, China
1 shared publication - Bin Zhou
CAS CEMCS-CUHK Joint Laboratory, New Cornerstone Science Laboratory, Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China
1 shared publication - Dan Tong
Department of Radiology, The First Hospital of Jilin University, Changchun, China
1 shared publication - Dandan Guo
Jilin University
1 shared publication - Guizhong Cui
Guangzhou National Laboratory, School of Basic Medical Sciences, Guangzhou Medical University 2 , Guangzhou 510005
1 shared publication Hongkun Shi
1 shared publication
Latest Publications
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
The feasibility of contrast-enhanced 3D T1WI reconstructed with Compressed SENSE Artificial Intelligence in evaluation of brain metastases
Contrast-enhanced (CE) 3D T1-weighted scanning has been used more frequently with better spatial resolution and thinner section than 2D T1-weighted images for early detection and response assessment of brain metastases. To further improve the image scanning sequence, a new reconstruction algorithm, Compressed-SENSE Artificial Intelligence (CS-AI) was applied experimentally to achieve a balance between shortened scan time and improved image quality. This study aims to investigate the feasibility of contrast-enhanced 3D T1-weighted MRI reconstructed with Compressed SENSE Artificial Intelligence (CS-AI) by comparing with 3D T1-weighted images reconstructed with Compressed SENSE(CS), and to find out the optimal acceleration factor(AF).
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
The feasibility of contrast-enhanced 3D T1WI reconstructed with Compressed SENSE Artificial Intelligence in evaluation of brain metastases
Contrast-enhanced (CE) 3D T1-weighted scanning has been used more frequently with better spatial resolution and thinner section than 2D T1-weighted images for early detection and response assessment of brain metastases. To further improve the image scanning sequence, a new reconstruction algorithm, Compressed-SENSE Artificial Intelligence (CS-AI) was applied experimentally to achieve a balance between shortened scan time and improved image quality. This study aims to investigate the feasibility of contrast-enhanced 3D T1-weighted MRI reconstructed with Compressed SENSE Artificial Intelligence (CS-AI) by comparing with 3D T1-weighted images reconstructed with Compressed SENSE(CS), and to find out the optimal acceleration factor(AF).
- Open Access
- 12 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (11) , eabb6260
M-CSF, IL-6, and TGF-β promote generation of a new subset of tissue repair macrophage for traumatic brain injury recovery
The combination use of TGF-β, M-CSF, and IL-6 represents a promising therapy to repair traumatic brain injury.
- 12 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (11) , eabb6260
Open AccessM-CSF, IL-6, and TGF-β promote generation of a new subset of tissue repair macrophage for traumatic brain injury recovery
The combination use of TGF-β, M-CSF, and IL-6 represents a promising therapy to repair traumatic brain injury.
- Open Access
- 1 May 2016
- Published by Elsevier in Value in Health
- Vol. 19 (3) , A143
Evaluating Expected Medication Costs and Budget Impact of Systemic Therapies for Unresectable/Metastatic Melanoma
- 1 May 2016
- Published by Elsevier in Value in Health
- Vol. 19 (3) , A143
Open AccessEvaluating Expected Medication Costs and Budget Impact of Systemic Therapies for Unresectable/Metastatic Melanoma